Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer

西妥昔单抗 医学 伊立替康 福尔菲里 内科学 肿瘤科 维持疗法 养生 叶酸 结直肠癌 临床终点 无进展生存期 癌症 随机对照试验 化疗
作者
Valérie Boige,Hélène Blons,Ετιεννε François,Méher Ben Abdelghani,Jean-Marc Phélip,Valérie Le Brun-Ly,Laurent Mineur,Marie Pierre Galais,Anne-Laure Villing,Vincent Hautefeuille,Laurent Miglianico,Christelle De La Fouchardière,Dominique Genet,Nadia Levasseur,Charles-Briac Levaché,Nicolas Penel,Emmanuel Mitry,Stéphane Jacquot,Thomas Aparicio,Emilie Brument,Sophie Gourgou,Florence Castan,Olivier Bouché
出处
期刊:JAMA network open [American Medical Association]
卷期号:6 (9): e2333533-e2333533 被引量:4
标识
DOI:10.1001/jamanetworkopen.2023.33533
摘要

Importance The optimal maintenance strategy after induction chemotherapy with anti–epidermal growth factor receptor antibody for patients with RAS wild-type metastatic colorectal cancer (mCRC) remains to be debated. Objective To evaluate the efficacy and safety of maintenance therapy with single-agent cetuximab after FOLFIRI (leucovorin [folinic acid], fluorouracil, and irinotecan) plus cetuximab induction therapy. Design, Setting, and Participants The TIME (Treatment After Irinotecan-Based Frontline Therapy: Maintenance With Erbitux]) (PRODIGE 28 [Partenariat de Recherche en Oncologie Digestive]–UCGI 27 [UniCancer GastroIntestinal Group]) phase 2 noncomparative, multicenter randomized clinical trial was conducted from January 15, 2014, to November 23, 2018, among 139 patients with unresectable RAS wild-type mCRC. The cutoff date for analysis was July 21, 2022. Interventions After first-line induction therapy with 8 cycles of FOLFIRI plus cetuximab, patients without disease progression were randomized (1:1) to biweekly maintenance with cetuximab or observation. On disease progression, the same induction regimen was recommended for 16 weeks followed by further maintenance with cetuximab or observation until disease progression under the full induction regimen. Main Outcomes and Measures The primary end point was the 6-month progression-free rate from randomization. Analysis was performed on an intention-to-treat basis. An exploratory biomolecular analysis, using next-generation sequencing, investigated the putative prognostic value of the tumor mutation profile. Results Of 214 patients enrolled (141 men [65.9%]; median age, 67 years [range, 23-85 years]), 139 were randomized to receive cetuximab (n = 67; 45 men [67.2%]; median age, 64 years [range, 34-85 years]) or to be observed (n = 72; 50 men [69.4%]; median age, 68 years [23-85 years]). The 6-month progression-free rate was 38.8% ([26 of 67] 95% CI, 27.1%-51.5%) in the cetuximab group and 5.6% ([4 of 72] 95% CI, 1.5%-13.6%) in the observation group. At a median follow-up of 40.5 months (95% CI, 33.6-47.5 months), median progression-free survival (PFS) from randomization was 5.3 months (95% CI, 3.7-7.4 months) in the cetuximab group and 2.0 months (95% CI, 1.8-2.7 months) in the observation group. Median overall survival (OS) was 24.8 months (95% CI, 18.7-30.4 months) in the cetuximab group and 19.7 months (95% CI, 13.3-24.4 months) in the observation group. In an exploratory multivariate analysis, any tumor-activating mutation in the mitogen-activated protein kinase (MAPK) pathway genes was associated with shorter PFS from randomization regardless of treatment group (hazard ratio, 1.63 [95% CI, 1.01-2.62]; P = .04). The most frequent grade 3 or 4 treatment-related toxic effect in the cetuximab group during maintenance therapy was rash (8 of 67 [11.9%]). Conclusion and Relevance The randomized clinical trial did not meet its primary end point but suggests clinically meaningful PFS and OS benefits associated with cetuximab maintenance therapy. However, maintenance cetuximab or treatment breaks after first-line combination FOLFIRI-cetuximab therapy seems inappropriate for patients with MAPK-mutated independently of the side of primary tumor. A more complete assessment of MAPK pathway mutations warrants further investigation to the refine treatment strategy for patients with RAS wild-type mCRC. Trial Registration ClinicalTrials.gov Identifier: NCT02404935
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
周shang完成签到,获得积分10
刚刚
1秒前
1秒前
隐形曼青应助邪恶摇粒绒采纳,获得10
2秒前
无花果应助ssk采纳,获得10
3秒前
3秒前
4秒前
5秒前
6秒前
记忆发布了新的文献求助10
7秒前
研研研完成签到,获得积分10
7秒前
潇洒花生完成签到 ,获得积分10
7秒前
7秒前
BioNiuma完成签到,获得积分10
8秒前
科研通AI2S应助SFYIII采纳,获得10
8秒前
11秒前
11秒前
风的季节完成签到,获得积分0
11秒前
单纯芹菜发布了新的文献求助10
12秒前
马麻薯完成签到,获得积分10
12秒前
13秒前
kkkkkkk发布了新的文献求助10
19秒前
整齐泥猴桃完成签到 ,获得积分10
21秒前
沉默的红牛完成签到 ,获得积分10
21秒前
动听的乐瑶完成签到,获得积分10
23秒前
桐桐应助xzy采纳,获得10
27秒前
小蘑菇应助互助遵法尚德采纳,获得10
28秒前
29秒前
Frieren完成签到 ,获得积分10
29秒前
29秒前
卜乌完成签到,获得积分10
30秒前
30秒前
科研通AI2S应助SFYIII采纳,获得10
32秒前
奶黄包完成签到,获得积分10
32秒前
Mr.Jian完成签到 ,获得积分10
33秒前
34秒前
我是老大应助mmmaple采纳,获得10
34秒前
34秒前
hzf发布了新的文献求助10
35秒前
BCKT完成签到,获得积分10
36秒前
高分求助中
Sustainability in Tides Chemistry 2000
Pharmacogenomics: Applications to Patient Care, Third Edition 1000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Ethnicities: Media, Health, and Coping 700
Genera Insectorum: Mantodea, Fam. Mantidæ, Subfam. Hymenopodinæ (Classic Reprint) 600
Development of a new synthetic process for the synthesis of (S)-methadone and (S)- and (R)-isomethadone as NMDA receptor antagonists for the treatment of depression 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3088895
求助须知:如何正确求助?哪些是违规求助? 2741067
关于积分的说明 7563024
捐赠科研通 2391205
什么是DOI,文献DOI怎么找? 1268199
科研通“疑难数据库(出版商)”最低求助积分说明 614019
版权声明 598684